Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.

Trial Details

NCT ID
NCT06895031
Phase
PHASE2
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • JYP0015
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
  • Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1
  • Adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →